Company profile
Ticker
TELO
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
872606031
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
15 Apr 24
8-K
Departure of Directors or Certain Officers
12 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Telomir Pharmaceuticals Announces Pricing of Initial Public Offering
13 Feb 24
424B4
Prospectus supplement with pricing info
12 Feb 24
424B1
Prospectus with pricing info
12 Feb 24
EFFECT
Notice of effectiveness
9 Feb 24
CERT
Certification of approval for exchange listing
8 Feb 24
8-A12B
Registration of securities on exchange
6 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
Latest ownership filings
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
30 Apr 24
Telomir Pharmaceuticals Unveils Pre-Clinical Data On Age-Reversal Drug Telomir-1 At National Press Club Event in Washington, D.C.
16 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
10 Apr 24
Telomir Pharmaceuticals' To Present Pre-Clinical Data For Age-Reversal Drug Telomir-1 At The National Press Club In Washington, DC, On April 15, 2024
2 Apr 24
Telomir Pharmaceuticals Collaborates With Argenta To Study Osteoarthritis In Canines
26 Mar 24
Press releases
Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines
26 Mar 24
Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th
22 Mar 24
Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science
14 Mar 24
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
7 Mar 24
Michael F. Roizen, MD to Increase Activities with Telomir Pharmaceuticals as Special Advisor on Age Reversal
5 Mar 24